Nebenwirkungen · Humira
Humira 80 mg solution for injection in pre-filled syringe Humira 80 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 127
HOS-112032 · Präparat HOS-093595
In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and 105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations ≥ 3 x ULN occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T11:41:00Z · SHA-256 0118f9ea31f7b28ac156bc8449293407c25bc43421a73fa92a30fe90db390eca · Passage b2917e1e030df2554fe2c74f8d1e11e1a7e5f0df889596c2f3fb1cf9202c5ee7 · Zeichen 24585–24971 im Abschnitt